Telix Pharmaceuticals has successfully priced and upsized its convertible bonds offering to US$600 million, up from the initially planned US$550 million, reflecting strong investor demand for the biopharmaceutical company’s debt instrument. The 1.50 per cent convertible notes due 2031 will be issued through Telix’s wholly-owned subsidiary and guaranteed by Telix and its US operating entity, creating a five-year financing solution that provides the company with meaningful financial flexibility.
The pricing details reveal a measured approach to conversion economics. The initial conversion price of US$13.85 per share, equivalent to approximately A$19.55, represents a 37.5 per cent premium to the reference share price of A$14.22. This premium sits within market norms for convertible bonds and reflects investor confidence in Telix’s share price trajectory over the five-year term. The reference price was established through a delta placement completed by sole bookrunner J.P. Morgan at an 8.0 per cent discount to Telix’s closing price on the day of announcement, suggesting the company’s equity capital structure remains attractive to both debt and equity investors.
The financing structure demonstrates thoughtful capital management. Telix intends to use the proceeds to refinance its existing A$650 million convertible bonds due 2029, with the company executing a concurrent repurchase of approximately A$637 million of those bonds, representing more than 85 per cent of the outstanding amount. The remaining bonds will be redeemed, effectively eliminating the 2029 maturity and replacing it with a 2031 maturity. This approach extends Telix’s debt runway while maintaining manageable coupon obligations at only 1.50 per cent per annum, substantially lower than typical corporate debt rates, which reflects the conversion feature’s value to investors.
The inclusion of an investor put option at the end of year three provides bondholders with a liquidity event three years before maturity, offering them downside protection should the company’s circumstances deteriorate. This feature enhances the bonds’ attractiveness and likely contributed to the oversubscription that led to the US$50 million upsizing. Interest payments will commence on 22 July 2026 and occur quarterly thereafter, with settlement of both the new offering and concurrent repurchase expected on 22 April 2026, subject to customary closing conditions.
Managing Director and Group CEO Dr. Christian Behrenbruch framed the refinancing within Telix’s broader capital strategy, emphasizing the financial flexibility provided by the successful completion. The support from both existing and new investors during the bookbuilding process suggests confidence in the company’s pipeline and financial trajectory. For equity investors, the conversion premium and extended maturity profile indicate a measured approach to potential dilution. The next critical date to monitor is 22 April 2026 when settlement is expected to occur. Investors should also track developments in Telix’s clinical programs and commercial execution to assess whether the share price remains positioned for potential conversion. This announcement is price sensitive and has been flagged as material by the ASX.
View the full ASX announcement (PDF)
About TELIX Pharmaceuticals Limited (ASX: TLX)
TELIX Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals for oncology and other serious diseases. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions, focusing on targeted radiation therapies for various cancer indications. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
